-27%

est. 2Y upside i

CybersecuritySeries B

MedCrypt gives medical device vendors cybersecurity features in a few…

Rank

#456

Sector

Healthcare Cybersecurity

Est. Liquidity

~3Y

Data Quality

Data: Medium

MedCrypt presents a strong upside opportunity for a job seeker, with an estimated expected return of 119% over a two-year horizon.

Last updated: March 10, 2026

Bull (35%)+250%

MedCrypt's Security Intelligence Platform achieves rapid adoption among top global medical device manufacturers, driving revenue to $30M+ by 2028. Continued 100% FDA submission approval solidifies its market leadership, justifying a 30x revenue multiple and a $770M valuation.

Base (50%)+75%

MedCrypt maintains its strong position, growing its customer base and expanding platform features in line with market demand. Revenue reaches $20M by 2028, with a 25x revenue multiple, leading to a $385M valuation.

Bear (15%)-40%

Increased competition from larger cybersecurity firms or slower-than-expected market adoption limits growth. Revenue stalls at $15M by 2028, and a compressed 10x revenue multiple results in a $132M valuation, significantly impacting common stock value.

Est. time to liquidity~2.5 years

Preference Stack Risk

high

Investors hold $36.4M in liquidation preferences ahead of common shareholders. In an exit at or below the estimated $220M current valuation, common stock value would be significantly impacted.

Dilution Risk

moderate

As a Series B company, it is likely to raise at least one more significant funding round (e.g., Series C) before an exit, which will dilute existing equity holders.

Secondary Liquidity

none

There is no indication of an active secondary market for MedCrypt shares, meaning liquidity for employee equity is tied to a future acquisition or IPO.

Questions to Ask at the Interview

Strategic questions based on MedCrypt's data — designed to show you've done your homework.

  • 1

    “Given the 50% YoY customer growth and the launch of new platforms like Security Intelligence, how does MedCrypt plan to scale its sales and implementation teams to meet this surging demand while maintaining its high FDA submission approval rate?”

  • 2

    “The medical device security market is attracting larger players like Palo Alto Networks and Armis. How does MedCrypt plan to leverage its deep regulatory expertise and specialized focus to maintain its competitive moat against these broader cybersecurity giants?”

  • 3

    “With total funding at $36.4M and a Series B round in late 2022, what is the company's current valuation strategy, and what are the anticipated timelines and potential exit paths for achieving liquidity for employee equity?”

Community

Valuation Sentiment

Our model estimates -27% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.